
Opinion|Videos|June 16, 2025
Top-Line Results of the Phase 3 ZIRCON Study
Panelists discuss how the ZIRCON trial results showed impressive test characteristics with 95% positive predictive value for clear cell renal cell carcinoma, meaning a positive test strongly indicates cancer requiring treatment.
Advertisement
Episodes in this series

Diagnostic Performance of the ZIRCON Trial
Main Discussion Topics:
- A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC)
- A 75% negative predictive value
- Important observation that non–clear cell positive cases were still malignant
- A positive test indicates cancer with high probability.
Key Points for Physicians:
- When the test is positive, there is a greater than 90% probability of ccRCC.
- The 7% of positive tests that weren’t ccRCC were still malignant tumors.
- A positive test strongly supports proceeding with intervention.
- A simplified interpretation: If it lights up, it’s very likely cancer.
Notable Insights:
A key clinical value is that a positive test is highly reliable for indicating malignancy, even in the small percentage that aren’t specifically ccRCC.
Clinical Significance:
The high positive predictive value provides actionable information that can guide clinical decision-making toward appropriate intervention.
Advertisement
Related to this article

Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.

A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
4
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
5

